Announced
Completed
BioAtla completed a $72m Series D funding round.
Financials
Transaction Value£55m
Consideration TypeCash
Capital Owned-
Capital Bid For-
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-
Sources
Tags
Private
antibody therapeutics
Minority
Acquisition
Cross Border
Friendly
Pharmaceuticals
Completed
United States
Private Equity
biological products
Venture Capital
Synopsis
Soleus Capital, HBM Healthcare, Cormorant Asset, Farallon Capital, Pappas Capital, Janus Henderson, Boxer Capital and Pfizer Ventures invested $72m Series D funding round in BioAtla, a biological service company.
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
No credit card required
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.